The 8F10 monoclonal antibody specifically recognizes CD267 which is also known as transmembrane activator and calcium-modulating and cyclophilin ligand interactor(transmembrane activator and CAML interactor or TACI). CD267 is encoded by Tnfrsf13b (tumor necrosis factor receptor superfamily member 13B). CD267 is a type III transmembrane protein receptor that binds to the ligands BAFF (BLyS), and APRIL. BAFF overproduction is associated with lupus erythematosus and Sjögren's disease, two systemic autoimmune diseases. CD267 is expressed most notably on maturing subsets of splenic B cells such as transition type 2 (T2) and marginal zone (MZ) B cells and also in activated T-cells. In CD267 deficient mice, B cell numbers are increased and mice develop autoimmune disorders suggesting that CD267 plays a role in B cell regulation.
The antibody was conjugated to an oligonucleotide that contains an antibody clone-specific barcode (ABC) flanked by a poly-A tail on the 3' end and a PCR handle (PCR primer binding site) on the 5' end. The ABC for this antibody was designed to be used with other BD AbSeq oligonucleotides conjugated to other antibodies. All AbSeq ABC sequences were selected in silico to be unique from human and mouse genomes, have low predicted secondary structure, and have high Hamming distance within the BD AbSeq portfolio, to allow for sequencing error correction and unique mapping. The poly-A tail of the oligonucleotide allows the ABC to be captured by the BD Rhapsody™ system. The 5' PCR handle allows for efficient sequencing library generation for Illumina sequencing platforms.
NOTE: The BD Rhapsody Single-Cell Analysis System must be used with the BD Rhapsody Express Instrument.